With shares of Amazon (NASDAQ:AMZN) trading around $403, is AMZN an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementAmazon serves its customers through its retail websites and focus on selection, price, and convenience. The company also manufactures and sells Kindle devices. Amazon offers programs that enable sellers to sell their products on the company�� websites, including the sellers��own branded websites, and fulfill orders through them. Amazon also provides platforms that allow authors, musicians, filmmakers, app developers, and others to publish and sell content. Online commerce has been on the rise because of the convenience, efficiency, and relatively low prices offered.
It was a lucrative holiday shopping season for Amazon.com, but the e-commerce giant still left some shoppers disgruntled after Santa Claus failed to show up on time. According to Bloomberg, despite Amazon�� promise that all of its ordered packages would be delivered by Christmas, some shoppers still suffered empty doorsteps on the eve of the big day, and now the largest online retailer is working to make it up to them.�For those affected by Amazon�� inability to deliver packages the time, the Seattle, Washington-based retailer offered customers $20 gift cards and refunds on shipping charges — along with a promise that it would never happen again. Amazon doesn�� take full responsibility for the shipping shortcomings, as it cites failures in the United Parcel Service�� (NYSE:UPS) transportation network in addition to its onslaught of last-minute orders, but the company issued gift cards to compensate customers nonetheless, and promised to look into UPS difficulties.
5 Best India Stocks To Own Right Now: Research Frontiers Incorporated(REFR)
Research Frontiers Incorporated engages in the development, licensing, and marketing of technology and devices to control the flow of light. The company licenses its suspended particle device (SPD-Smart) light-control technology to companies that manufacture and market the SPD-smart chemical emulsion, light-control film made from chemical emulsion, lamination services, and electronics to power end-products incorporating the film; and end-products, such as windows, skylights, and sunroofs. The SPD-Smart light-control technology is used for various applications, such as windows, skylights, partitions, doors, and sunshades for the architectural, aircraft, marine, automotive, and appliance industries; variable light transmission sunglasses, goggles, visors, and other eyewear; variable light transmission automotive sunroofs, sunvisors, and rear-view mirrors; and flat panel information displays for use in billboards, scoreboards, point-of-purchase advertising displays, traffic s igns, computers, telephones, PDAs, and other electronic instruments. The company was founded in 1965 and is headquartered in Woodbury, New York.
Advisors' Opinion:- [By Garrett Cook]
In trading on Friday, cyclical consumer goods & services shares gained 0.61 percent. Top gainers in the sector included Nike (NYSE: NKE), up 10 percent, and Research Frontiers (NASDAQ: REFR), up 5.6 percent.
5 Best Low Price Stocks To Watch For 2014: Aqua America Inc.(WTR)
Aqua America, Inc., through its subsidiaries, operates regulated utilities that provide water or wastewater services in the United States. The company serves residential, commercial, fire protection, industrial, and other water and wastewater customers in Pennsylvania, Texas, North Carolina, Ohio, Illinois, New Jersey, New York, Florida, Indiana, Virginia, Maine, Missouri, and Georgia. It also provides water and wastewater services through operating and maintenance contracts with municipal authorities and other parties, as well as sludge hauling, septage and grease services, and backflow prevention services. The company was formerly known as Philadelphia Suburban Corporation and changed its name to Aqua America, Inc. in 2004. Aqua America, Inc. was founded in 1968 and is based in Bryn Mawr, Pennsylvania.
Advisors' Opinion:- [By David Dittman]
Note that water utilities and UF Portfolio Holdings American Water Works Co Inc (NYSE: AWK), Aqua America Inc (NYSE: WTR) and Connecticut Water Service Inc (NSDQ: CTWS) posted 2013 total returns of 16.1 percent, 18.8 percent and 23.1 percent, respectively, underperforming the broader S&P 500 but besting the traditional safe-haven subgroups.
5 Best Low Price Stocks To Watch For 2014: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By Ben Levisohn]
Shares of Gilead (GILD) and Celgene (CELG) have tumbled today after both companies revealed that they were facing patent pressures.
For Gilead, Idenix Pharmaceuticals (IDIX) filed a patent-infringement lawsuit that appears to target Gilead’s Sovaldi (someone please correct me if I’m wrong). For Celgene, it was the decision of a New Jersey court to schedule a hearing on a patent case for April 29, earlier than expected. It hasn’t helped that the UK’s National Institute for Health and Care Excellence also said that Celgene’s Revlimid doesn’t work well enough to be covered for “second line treatment of multiple myeloma.”
- [By Bryan Murphy]
When investors think of non-Hodgkin's lymphoma stocks, big names like Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) come to mind. Both GILD and CELG are making prolific progress in the war on NHL, and both are fine, well-positioned companies. It's little Infinity Pharmaceuticals Inc. (NASDAQ:INFI) that may end up making the proverbial quantum leap in the non-Hodgkin's lymphoma stocks arena, however, and better still, it's INFI shares that may well end up doling out a much bigger reward than Gilead or Celgene could to newcomers.
5 Best Low Price Stocks To Watch For 2014: China Ming Yang Wind Power Group Ltd (MY)
China Ming Yang Wind Power Group Limited incorporated on February 26, 2009, is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company�� products consist of basic models of wind turbines, each with a rated power capacity of 1.5 megawatt (MW); wind turbines with a rated power capacity of 2.0MW, and 2.5/3.0MW SCD wind turbines. Each product type may be installed with one of three rotor blade models depending on the location and wind conditions. As of December 31, 2012, the Company had entered into sales contracts with 37 end customers to deliver 3,730 units of its wind turbines.
It cooperates with aerodyn Energiesysteme to develop its 1.5 megawatt wind turbines and share intellectual property rights. It also has obtained licenses from aerodyn Asia Co., Ltd. (aerodyn Asia) to manufacture and distribute wind turbines utilizing its super-compact drive (SCD) technology, with a rated power capacity of 6.0MW.
The Company�� customers are the Chinese state-owned power producers which include Huaneng, China Datang, Huadian, China Guodian Corporation, and China Power Investment Corporation (CPIC) or their alternative energy subsidiaries, such as China Longyuan Power Group Corporation Limited (Longyuan), a subsidiary of Guodian, and China Datang Corporation Renewable Power Co., Limited (Datang Renewable), a subsidiary of China Datang. It also sells wind turbines to regional alternative energy investment companies, regional power producers and wind farm operators in the private sector. Its facilities are located in Zhongshan, Tianjin, Jilin, Rudong, Dali and Inner Mongolia in China.
The Company produces megawatt-class, grid-connected, horizontal-axis wind turbines, equipped with a double-fed constant frequency induction generator, which is a design of the generator that enables the generator to produce electric current of a constant frequency as the shaft rotates at varying speeds causing! the generator rotor to rotate at varying speed. It offers 1.5 megawatt turbines specially designed and developed for the wind and weather conditions and power grids in China. Its 1.5 megawatt wind turbines are equipped with rotor blades with a post-installation diameter of 77.1 meters, 82.6 meters or 89.0 meters.
The Company has license rights under a license agreement from aerodyn Asia to manufacture and distribute 2.5/3.0MW SCD wind turbines and 6.0MW SCD wind turbines in China. The Company is focused on developing 3.8MW wind turbine model for larger multi-megawatt wind turbines.
The Company competes with Sinovel, Goldwind, Dongfang Electric, United Power, Vestas, Gamesa Corporacion Tecnologica S.A. and GE Energy.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that looks ready to trigger a big breakout trade is China Ming Yang Wind Power Group (MY), a wind turbine manufacturer in China. This stock has been very hot over the last six months, with shares up sharply by 52%.
If you take a look at the chart for China Ming Yang Wind Power Group, you'll notice that this stock has been uptrending over the last few weeks, with shares moving higher from its low of $1.91 to its intraday high of $2.59 a share. During that uptrend, shares of MY have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of MY within range of triggering a big breakout trade.
Market players should now look for long-biased trades in MY if it manages to break out above some past overhead resistance levels at $2.58 to $2.80 a share high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.56 million shares. If that breakout hits soon, then MY will set up to re-test or possibly take out its next major overhead resistance levels at $3.35 to its 52-week high at $3.52 a share. Any high-volume move above those levels will then give MY a chance to tag $4 a share.
Traders can look to buy MY off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $2.30 a share, or near more support at $2.02 a share. One can also buy MY off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Garrett Cook]
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.
- [By John Udovich]
Small cap Ocean Power Technologies Inc (NASDAQ: OPTT) just sank 34% on news that they have fired their CEO "for cause,��meaning its worth taking a closer look at the stock to see if there is anything to salvage (shares were rising more than 6% in after hours) plus take a look at the performance of potential renewable energy related peers like Ormat Technologies, Inc (NYSE: ORA), Broadwind Energy Inc (NASDAQ: BWEN) and China Ming Yang Wind Power Group Ltd (NYSE: MY).
- [By John Udovich]
Small cap wind stock Broadwind Energy Inc (NASDAQ: BWEN) is up 203.7% since the start of the year, but investors might want to contain their excitement when they look closer at the�stock and�consider its�long term performance along with the performance of other wind investments like First Trust Global Wind Energy ETF (NYSEARCA: FAN) and wind energy stocks Vestas Wind Systems (OTCMKTS: VWDRY) and China Ming Yang Wind Power Group Ltd (NYSE: MY) to see whether BWEN is just blowing more hot air.
No comments:
Post a Comment